Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas

Suzanne George, Priscilla Merriam, Robert G. Maki, Annick D. Van Den Abbeele, Jeffrey T. Yap, Timothy Akhurst, David C. Harmon, Gauri Bhuchar, Margaret M. O'Mara, David R. D'Adamo, Jeffrey Morgan, Gary K. Schwartz, Andrew J. Wagner, James E. Butrynski, George D. Demetri, Mary L. Keohan

Research output: Contribution to journalArticlepeer-review

270 Scopus citations


Purpose: To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas. Patients and Methods: A total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily. Primary end point was Response Evaluation Criteria in Solid Tumors defined response. Secondary end points were stable disease at 16 and 24 weeks. [18F]- fluorodeoxyglucose positron emission tomography was performed on a subset of 24 patients at baseline and after 10 to 14 days of therapy. Results: Forty-eight patients were eligible for response. One patient (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 weeks. Ten patients (20%) achieved stable disease for at least 16 weeks. Metabolic PR was seen in 10 (47%) of 21 of patients. Metabolic stable disease was seen in 11 (52%) of 21. There were no unexpected toxicities observed. Conclusion: Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.

Original languageEnglish
Pages (from-to)3154-3160
Number of pages7
JournalJournal of Clinical Oncology
Issue number19
StatePublished - 1 Jul 2009


Dive into the research topics of 'Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas'. Together they form a unique fingerprint.

Cite this